What to expect on Semaglutide: a week-by-week timeline
Most of what you'll read about semaglutide is written by someone who profits when you start a prescription. This isn't that.
This guide covers injectable semaglutide — Wegovy, Ozempic, compounded versions. For oral semaglutide (Rybelsus), the dose schedule and adjustment period differ. Talk to your provider.
For injection supplies and self-administration basics, see the Injectable Peptide Supplies Guide
- Subtle appetite reduction with shifting food preferences. Patient-reported data describes it as “I left food on my plate without thinking about it” rather than dramatic hunger suppression. Some experience the early version of what's called “food noise” reduction. High-fat or heavily processed foods may become less appealing.
- Mild nausea, the most commonly documented side effect. Typically peaks 24–72 hours after a dose and improves with each subsequent dose at the same level.
- Fatigue. A 2026 Nature Health study from Penn analyzing patient-reported outcomes at scale found fatigue is the second most commonly reported symptom — underrepresented in clinical trial adverse event data.
- Constipation from slowed gastric emptying. Providers commonly recommend gradual increases in hydration and fiber.
- Injection site reactions (redness, mild swelling) reported in about 3–5% of clinical trial participants.
- Minimal weight change. Early scale movement is mostly fluid shifts. The starting dose is a ramp-up, not a treatment dose.
When to contact your provider
Across all phases, these signals warrant reaching out to your prescriber:
- Vomiting that prevents keeping food or fluids down for more than 24 hours
- Severe abdominal pain — sharp, persistent or radiating to the back (pancreatitis is listed as a risk in the prescribing information)
- Signs of allergic reaction: rash, itching, swelling of face/tongue/throat, difficulty breathing
- Dizziness that interferes with daily activities, especially if you're on blood pressure medication
Labs worth discussing with your provider
Your provider will determine what's appropriate for your situation. These are markers clinical guidelines and prescribing information suggest are relevant for tracking response.
For baseline labs to discuss before starting treatment, see the Semaglutide compound profile page.
- HbA1c — the primary efficacy marker. Expect a 1.0–1.5 percentage point reduction from baseline at 12 weeks. This is the FDA-validated endpoint that anchors GLP-1 trials.
- Fasting insulin — expect a decrease, reflecting improved insulin sensitivity from both weight loss and direct GLP-1 mechanism. Most providers don't order it. Ask for it explicitly.
- Triglycerides and ApoB — expect both to decrease. ApoB is the more predictive cardiovascular risk marker, but most providers run a standard lipid panel that doesn't include it. Ask for it.
- Repeat CMP — liver and kidney function check. No expected change but rules out adverse effects on hepatic or renal function.
What nobody tells you about stopping
Long-term follow-up data has documented that participants who completed 68 weeks of semaglutide and went off-treatment regained approximately two-thirds of their lost weight within one year. Published findings concluded ongoing treatment is required to maintain weight and health improvements.
For most patients, semaglutide functions as chronic therapy. There is no published evidence-based tapering protocol. If you started semaglutide with the intention of eventually stopping, discuss it with your provider early in treatment — not when you're ready to quit.